Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector
Through the Catalyst Awards program at its Clinical and Translational Science Institute, UCSF will give MedImmune access to a broad range of discovery and preclinical opportunities under a three-year agreement. Plus, Mallinckrodt buys Cadence, Debiopharm acquires Affinium’s antibiotics program, and more.
You may also be interested in...
After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.
The US FDA appears to have concerns about the device used to administer the vaccine.